RADX RAD 101 Phase IIb Second Interim Data Analysis Approximately three months after the first interim readout from the RAD 101 Phase IIb trial, Radiopharm Theranostics Limited (NASDAQ: RADX) ...

Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...

Diamyd Medical on Friday March 27th announced that the pre-specified interim efficacy analysis on 174 out of 321 participants of the ongoing Phase 3 DIAGNODE-3 trial yielded results that were unexpect ...

SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, ...

Phase shift analysis remains a cornerstone of modern scattering theory, underpinning our understanding of how particles interact under various potential fields. By examining the phase differences ...

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis Claudin 18.2 is emerging as a target of clinical ...

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data ...